C
Edwards Lifesciences Corporation
EW
$68.51
$0.120.18%
C
Hold
8/26/2024Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 8/26/2024 due to a decline in the total return index, efficiency index and volatility index.
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 8/26/2024 due to a decline in the total return index, efficiency index and volatility index.
C
Hold
3/7/2024Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to C from C- on 3/7/2024 due to an increase in the total return index, growth index and volatility index. EBIT increased 43.7% from $420.6M to $604.4M, and total revenue increased 3.59% from $1.48B to $1.53B.
Edwards Lifesciences Corporation (EW) was upgraded to C from C- on 3/7/2024 due to an increase in the total return index, growth index and volatility index. EBIT increased 43.7% from $420.6M to $604.4M, and total revenue increased 3.59% from $1.48B to $1.53B.
C
Hold
10/11/2023Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 10/11/2023 due to a large decline in the growth index. Operating cash flow declined 89.3% from $314.1M to $33.6M, EBIT declined 21.84% from $395.6M to $309.2M, and earnings per share declined from $0.56 to $0.5.
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 10/11/2023 due to a large decline in the growth index. Operating cash flow declined 89.3% from $314.1M to $33.6M, EBIT declined 21.84% from $395.6M to $309.2M, and earnings per share declined from $0.56 to $0.5.
C
Hold
3/16/2023Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to C from C- on 3/16/2023 due to an increase in the total return index, valuation index and volatility index.
Edwards Lifesciences Corporation (EW) was upgraded to C from C- on 3/16/2023 due to an increase in the total return index, valuation index and volatility index.
C
Hold
1/17/2023Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 1/17/2023 due to a decline in the total return index and valuation index.
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 1/17/2023 due to a decline in the total return index and valuation index.
C
Hold
12/30/2022Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to C from C- on 12/30/2022 due to an increase in the volatility index and valuation index.
Edwards Lifesciences Corporation (EW) was upgraded to C from C- on 12/30/2022 due to an increase in the volatility index and valuation index.
C
Hold
12/15/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 12/15/2022 due to a noticeable decline in the total return index and volatility index.
Edwards Lifesciences Corporation (EW) was downgraded to C- from C on 12/15/2022 due to a noticeable decline in the total return index and volatility index.
C
Hold
10/28/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C from C+ on 10/28/2022 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.65 to $0.55, operating cash flow declined 6.71% from $332.2M to $309.9M, and total revenue declined 4% from $1.37B to $1.32B.
Edwards Lifesciences Corporation (EW) was downgraded to C from C+ on 10/28/2022 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.65 to $0.55, operating cash flow declined 6.71% from $332.2M to $309.9M, and total revenue declined 4% from $1.37B to $1.32B.
C
Hold
9/22/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B- on 9/22/2022 due to a decline in the volatility index, total return index and valuation index.
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B- on 9/22/2022 due to a decline in the volatility index, total return index and valuation index.
B
Buy
9/7/2022Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B- from C+ on 9/7/2022 due to an increase in the valuation index.
Edwards Lifesciences Corporation (EW) was upgraded to B- from C+ on 9/7/2022 due to an increase in the valuation index.
C
Hold
8/1/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B- on 8/1/2022 due to a noticeable decline in the valuation index, growth index and total return index.
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B- on 8/1/2022 due to a noticeable decline in the valuation index, growth index and total return index.
B
Buy
6/13/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 6/13/2022 due to a noticeable decline in the volatility index and total return index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 6/13/2022 due to a noticeable decline in the volatility index and total return index.
B
Buy
5/5/2022Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 5/5/2022 due to an increase in the growth index, valuation index and efficiency index. EBIT increased 22% from $363.1M to $443M, net income increased 11.42% from $335.3M to $373.6M, and earnings per share increased from $0.5299 to $0.59.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 5/5/2022 due to an increase in the growth index, valuation index and efficiency index. EBIT increased 22% from $363.1M to $443M, net income increased 11.42% from $335.3M to $373.6M, and earnings per share increased from $0.5299 to $0.59.
B
Buy
3/25/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 3/25/2022 due to a decline in the volatility index and valuation index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 3/25/2022 due to a decline in the volatility index and valuation index.
B
Buy
2/24/2022Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 2/24/2022 due to an increase in the growth index, valuation index and volatility index. Total revenue increased 1.49% from $1.31B to $1.33B.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 2/24/2022 due to an increase in the growth index, valuation index and volatility index. Total revenue increased 1.49% from $1.31B to $1.33B.
B
Buy
1/27/2022Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/27/2022 due to a substantial decline in the total return index and volatility index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/27/2022 due to a substantial decline in the total return index and volatility index.
B
Buy
12/22/2021Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 12/22/2021 due to a substantial increase in the total return index and volatility index.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 12/22/2021 due to a substantial increase in the total return index and volatility index.
B
Buy
12/7/2021Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 12/7/2021 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.78 to $0.54, EBIT declined 10.36% from $441.9M to $396.1M, and total revenue declined 4.78% from $1.38B to $1.31B.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 12/7/2021 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.78 to $0.54, EBIT declined 10.36% from $441.9M to $396.1M, and total revenue declined 4.78% from $1.38B to $1.31B.
B
Buy
7/30/2021Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from C+ on 7/30/2021 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 75.07% from $300.5M to $526.1M, earnings per share increased from $0.54 to $0.78, and EBIT increased 14.66% from $385.4M to $441.9M.
Edwards Lifesciences Corporation (EW) was upgraded to B from C+ on 7/30/2021 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 75.07% from $300.5M to $526.1M, earnings per share increased from $0.54 to $0.78, and EBIT increased 14.66% from $385.4M to $441.9M.
C
Hold
10/28/2020Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to C+ from C on 10/28/2020 due to a significant increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.2 to $0.52, EBIT increased 55.44% from $229.8M to $357.2M, and total revenue increased 23.34% from $925M to $1.14B.
Edwards Lifesciences Corporation (EW) was upgraded to C+ from C on 10/28/2020 due to a significant increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.2 to $0.52, EBIT increased 55.44% from $229.8M to $357.2M, and total revenue increased 23.34% from $925M to $1.14B.
C
Hold
7/29/2020Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C from B- on 7/29/2020 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.49 to -$0.2, EBIT declined 37.62% from $368.4M to $229.8M, and total revenue declined 18.05% from $1.13B to $925M.
Edwards Lifesciences Corporation (EW) was downgraded to C from B- on 7/29/2020 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.49 to -$0.2, EBIT declined 37.62% from $368.4M to $229.8M, and total revenue declined 18.05% from $1.13B to $925M.
B
Buy
4/6/2020Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 4/6/2020 due to a major decline in the volatility index and total return index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 4/6/2020 due to a major decline in the volatility index and total return index.
B
Buy
2/18/2020Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 2/18/2020 due to a noticeable increase in the valuation index, growth index and solvency index. EBIT increased 15.57% from $299.9M to $346.6M, total revenue increased 7.32% from $1.09B to $1.17B, and debt to equity declined from 0.16 to 0.15.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 2/18/2020 due to a noticeable increase in the valuation index, growth index and solvency index. EBIT increased 15.57% from $299.9M to $346.6M, total revenue increased 7.32% from $1.09B to $1.17B, and debt to equity declined from 0.16 to 0.15.
B
Buy
1/21/2020Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/21/2020 due to a noticeable decline in the total return index, efficiency index and growth index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/21/2020 due to a noticeable decline in the total return index, efficiency index and growth index.
B
Buy
10/29/2019Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 10/29/2019 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 28.17% from $341.2M to $437.3M, earnings per share increased from $1.14 to $1.3, and EBIT increased 6.16% from $282.5M to $299.9M.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 10/29/2019 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 28.17% from $341.2M to $437.3M, earnings per share increased from $1.14 to $1.3, and EBIT increased 6.16% from $282.5M to $299.9M.
B
Buy
7/26/2019Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B- from C+ on 7/26/2019 due to a major increase in the growth index, solvency index and volatility index. Operating cash flow increased 22,646.67% from $1.5M to $341.2M, and total revenue increased 9.46% from $993M to $1.09B.
Edwards Lifesciences Corporation (EW) was upgraded to B- from C+ on 7/26/2019 due to a major increase in the growth index, solvency index and volatility index. Operating cash flow increased 22,646.67% from $1.5M to $341.2M, and total revenue increased 9.46% from $993M to $1.09B.
C
Hold
7/11/2019Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B- on 7/11/2019 due to a major decline in the total return index and valuation index.
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B- on 7/11/2019 due to a major decline in the total return index and valuation index.
B
Buy
5/1/2019Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 5/1/2019 due to a large decline in the growth index, total return index and efficiency index. Operating cash flow declined 99.49% from $293M to $1.5M.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 5/1/2019 due to a large decline in the growth index, total return index and efficiency index. Operating cash flow declined 99.49% from $293M to $1.5M.
B
Buy
4/24/2019Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 4/24/2019 due to an increase in the valuation index and total return index.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 4/24/2019 due to an increase in the valuation index and total return index.
B
Buy
3/29/2019Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 3/29/2019 due to a decline in the valuation index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 3/29/2019 due to a decline in the valuation index.
B
Buy
2/15/2019Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 2/15/2019 due to an increase in the total return index, growth index and efficiency index. EBIT increased 16.73% from $250.4M to $292.3M, and total revenue increased 7.84% from $906.6M to $977.7M.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 2/15/2019 due to an increase in the total return index, growth index and efficiency index. EBIT increased 16.73% from $250.4M to $292.3M, and total revenue increased 7.84% from $906.6M to $977.7M.
B
Buy
1/3/2019Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/3/2019 due to a decline in the total return index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/3/2019 due to a decline in the total return index.
B
Buy
12/19/2018Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 12/19/2018 due to a noticeable increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.38 to 0.36, and the quick ratio increased from 1.62 to 1.69.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 12/19/2018 due to a noticeable increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.38 to 0.36, and the quick ratio increased from 1.62 to 1.69.
B
Buy
8/15/2018Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 8/15/2018 due to a large decline in the total return index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 8/15/2018 due to a large decline in the total return index.
B
Buy
7/27/2018Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from C+ on 7/27/2018 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from $0.96 to $1.32, the quick ratio increased from 1.48 to 1.62, and total revenue increased 5.46% from $894.8M to $943.7M.
Edwards Lifesciences Corporation (EW) was upgraded to B from C+ on 7/27/2018 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from $0.96 to $1.32, the quick ratio increased from 1.48 to 1.62, and total revenue increased 5.46% from $894.8M to $943.7M.
C
Hold
2/20/2018Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B on 2/20/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.79 to -$0.0133, net income declined 101.65% from $170.1M to -$2.8M, and total capital declined 4.86% from $4.2B to $3.99B.
Edwards Lifesciences Corporation (EW) was downgraded to C+ from B on 2/20/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.79 to -$0.0133, net income declined 101.65% from $170.1M to -$2.8M, and total capital declined 4.86% from $4.2B to $3.99B.
B
Buy
12/21/2017Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 12/21/2017 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 57.21% from $197.7M to $310.8M.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 12/21/2017 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 57.21% from $197.7M to $310.8M.
B
Buy
7/31/2017Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 7/31/2017 due to a major decline in the growth index. Earnings per share declined from $1.06 to $0.86, EBIT declined 18.6% from $310.2M to $252.5M, and total revenue declined 4.72% from $883.5M to $841.8M.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 7/31/2017 due to a major decline in the growth index. Earnings per share declined from $1.06 to $0.86, EBIT declined 18.6% from $310.2M to $252.5M, and total revenue declined 4.72% from $883.5M to $841.8M.
B
Buy
4/26/2017Upgraded
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 4/26/2017 due to a major increase in the total return index and growth index. Earnings per share increased from $0.65 to $0.7205, EBIT increased 7.58% from $195.3M to $210.1M, and total revenue increased 3.83% from $739.4M to $767.7M.
Edwards Lifesciences Corporation (EW) was upgraded to B from B- on 4/26/2017 due to a major increase in the total return index and growth index. Earnings per share increased from $0.65 to $0.7205, EBIT increased 7.58% from $195.3M to $210.1M, and total revenue increased 3.83% from $739.4M to $767.7M.
B
Buy
1/9/2017Downgrade
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/9/2017 due to a significant decline in the total return index, volatility index and efficiency index.
Edwards Lifesciences Corporation (EW) was downgraded to B- from B on 1/9/2017 due to a significant decline in the total return index, volatility index and efficiency index.
B
Buy
10/21/2016Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to B from B+ on 10/21/2016 due to a decline in the valuation index and total return index.
Edwards Lifesciences Corp. (EW) was downgraded to B from B+ on 10/21/2016 due to a decline in the valuation index and total return index.
B
Buy
7/29/2016Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to B+ from B on 7/29/2016 due to a substantial increase in the growth index, valuation index and volatility index. Operating cash flow increased 77.68% from $107.1M to $190.3M, total revenue increased 8.89% from $697.3M to $759.3M, and EBIT increased 6.22% from $202.5M to $215.1M.
Edwards Lifesciences Corp. (EW) was upgraded to B+ from B on 7/29/2016 due to a substantial increase in the growth index, valuation index and volatility index. Operating cash flow increased 77.68% from $107.1M to $190.3M, total revenue increased 8.89% from $697.3M to $759.3M, and EBIT increased 6.22% from $202.5M to $215.1M.
B
Buy
4/25/2016Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to B from B- on 4/25/2016 due to a large increase in the volatility index and total return index.
Edwards Lifesciences Corp. (EW) was upgraded to B from B- on 4/25/2016 due to a large increase in the volatility index and total return index.
B
Buy
3/11/2016Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to B- from B on 3/11/2016 due to a significant decline in the volatility index, growth index and valuation index. Operating cash flow declined 48.74% from $202.5M to $103.8M.
Edwards Lifesciences Corp. (EW) was downgraded to B- from B on 3/11/2016 due to a significant decline in the volatility index, growth index and valuation index. Operating cash flow declined 48.74% from $202.5M to $103.8M.
B
Buy
12/17/2015Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to B from A on 12/17/2015 due to a substantial decline in the valuation index.
Edwards Lifesciences Corp. (EW) was downgraded to B from A on 12/17/2015 due to a substantial decline in the valuation index.
A
Buy
12/11/2015Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to A from B on 12/11/2015 due to a substantial increase in the total return index, valuation index and growth index. Operating cash flow increased 19.05% from $170.1M to $202.5M, EBIT increased 6.95% from $146.8M to $157M, and earnings per share increased from $1.02 to $1.07.
Edwards Lifesciences Corp. (EW) was upgraded to A from B on 12/11/2015 due to a substantial increase in the total return index, valuation index and growth index. Operating cash flow increased 19.05% from $170.1M to $202.5M, EBIT increased 6.95% from $146.8M to $157M, and earnings per share increased from $1.02 to $1.07.
B
Buy
7/31/2015Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to B from A- on 7/31/2015 due to a significant decline in the valuation index, growth index and volatility index. EBIT declined 11.25% from $165.4M to $146.8M, and earnings per share declined from $1.12 to $1.02.
Edwards Lifesciences Corp. (EW) was downgraded to B from A- on 7/31/2015 due to a significant decline in the valuation index, growth index and volatility index. EBIT declined 11.25% from $165.4M to $146.8M, and earnings per share declined from $1.12 to $1.02.
A
Buy
7/13/2015Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to A- from A on 7/13/2015 due to a decline in the total return index and valuation index.
Edwards Lifesciences Corp. (EW) was downgraded to A- from A on 7/13/2015 due to a decline in the total return index and valuation index.
A
Buy
6/26/2015Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to A from A- on 6/26/2015 due to an increase in the total return index.
Edwards Lifesciences Corp. (EW) was upgraded to A from A- on 6/26/2015 due to an increase in the total return index.
A
Buy
6/11/2015Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to A- from A on 6/11/2015 due to a major decline in the total return index.
Edwards Lifesciences Corp. (EW) was downgraded to A- from A on 6/11/2015 due to a major decline in the total return index.
A
Buy
12/24/2014Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to A from A- on 12/24/2014 due to a noticeable increase in the total return index.
Edwards Lifesciences Corp. (EW) was upgraded to A from A- on 12/24/2014 due to a noticeable increase in the total return index.
A
Buy
11/28/2014Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to A- from B+ on 11/28/2014 due to an increase in the total return index, volatility index and solvency index.
Edwards Lifesciences Corp. (EW) was upgraded to A- from B+ on 11/28/2014 due to an increase in the total return index, volatility index and solvency index.
B
Buy
11/12/2014Downgrade
Edwards Lifesciences Corp. (EW) was downgraded to B+ from A- on 11/12/2014 due to a noticeable decline in the growth index, valuation index and volatility index. Operating cash flow declined 98.43% from $778M to $12.2M, and earnings per share declined from $5.09 to $0.87.
Edwards Lifesciences Corp. (EW) was downgraded to B+ from A- on 11/12/2014 due to a noticeable decline in the growth index, valuation index and volatility index. Operating cash flow declined 98.43% from $778M to $12.2M, and earnings per share declined from $5.09 to $0.87.
A
Buy
8/6/2014Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to A- from B on 8/6/2014 due to a significant increase in the valuation index, growth index and volatility index. Earnings per share increased from $0.56 to $5.09, operating cash flow increased 460.12% from $138.9M to $778M, and EBIT increased 27.59% from $93.5M to $119.3M.
Edwards Lifesciences Corp. (EW) was upgraded to A- from B on 8/6/2014 due to a significant increase in the valuation index, growth index and volatility index. Earnings per share increased from $0.56 to $5.09, operating cash flow increased 460.12% from $138.9M to $778M, and EBIT increased 27.59% from $93.5M to $119.3M.
B
Buy
6/30/2014Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to B from B- on 6/30/2014 due to a noticeable increase in the total return index, volatility index and valuation index.
Edwards Lifesciences Corp. (EW) was upgraded to B from B- on 6/30/2014 due to a noticeable increase in the total return index, volatility index and valuation index.
B
Buy
5/16/2014Upgraded
Edwards Lifesciences Corp. (EW) was upgraded to B- from C+ on 5/16/2014 due to an increase in the efficiency index, volatility index and total return index.
Edwards Lifesciences Corp. (EW) was upgraded to B- from C+ on 5/16/2014 due to an increase in the efficiency index, volatility index and total return index.
NYSE
03/12/2025 4:00PM Eastern
Quotes delayed
